AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29236529 — intervention group
Group type: EXPERIMENTAL
Intervention: Warnings with greater size (20%, 30%, or 50%)
Number of subjects: 544
Study 29236529 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette users
Number of subjects: 544
Study 29236529 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to warning labels
Number of subjects: 544
Study 29236529 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message recall
Number of subjects: 544
Study 28386837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion
Number of subjects: 90
Study 28386837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25403646 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (400 mg daily)
Number of subjects: 8399
Study 25403646 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg daily)
Number of subjects: 8399
Study 22782459 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib plus risperidone
Number of subjects: 40
Study 22782459 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus risperidone
Number of subjects: 40
Study 21728004 — intervention group
Group type: EXPERIMENTAL
Intervention: Berbamine
Number of subjects: 63
Study 21728004 — intervention group
Group type: COMPARATOR
Intervention: Control (no berbamine)
Number of subjects: 63
Study 19061537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 microg/day, once daily
Number of subjects: 446
Study 19061537 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (FPNS), 200 microg/day, twice daily
Number of subjects: 446
Study 19061537 — intervention group
Group type: COMPARATOR
Intervention: FFNS placebo
Number of subjects: 446
Study 19061537 — intervention group
Group type: COMPARATOR
Intervention: FPNS placebo
Number of subjects: 446
Study 16505427 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U subcutaneously weekly (40K arm)
Number of subjects: 365
Study 16505427 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 120,000 U subcutaneously every 3 weeks (120K arm)
Number of subjects: 365
Study 15284376 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d of elemental iron alone
Number of subjects: 90
Study 15284376 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/d of elemental iron in combination with multimicronutrients
Number of subjects: 90
Study 15284376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11052409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) at a mean dose of 80 mg (1.8 mg/kg/day) during the open phase
Number of subjects: 35
Study 11052409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) during the discontinuation phase
Number of subjects: 35
Study 11052409 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the discontinuation phase
Number of subjects: 35
Study 9333770 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH-receptor antibodies (TRAb) detection
Number of subjects: 313
Study 9333770 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroperoxidase antibodies (TPO‐Ab) estimation
Number of subjects: 313
Study 9333770 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrostatic treatment of Graves' disease
Number of subjects: 313
Study 9333770 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal thyroidectomy
Number of subjects: 313
Study 8039151 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine plus doxorubicin
Number of subjects: 0
Study 8039151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and 5-FU (CEF)
Number of subjects: 0
Study 8039151 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF with G-CSF
Number of subjects: 0
Study 8039151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 0
Study 2768607 — intervention group
Group type: EXPERIMENTAL
Intervention: Slide/tape program presenting procedures involved in cesarean delivery
Number of subjects: 42
Study 2768607 — intervention group
Group type: COMPARATOR
Intervention: Neutral information program
Number of subjects: 42
Study 869291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 52
Study 869291 — intervention group
Group type: COMPARATOR
Intervention: Xanthinol nicotinate
Number of subjects: 52
Study 31855037 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 122
Study 31855037 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 122
Study 30146591 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI (paroxetine, escitalopram)
Number of subjects: 55
Study 30146591 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI (duloxetine)
Number of subjects: 55
Study 28017188 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 42
Study 28017188 — intervention group
Group type: COMPARATOR
Intervention: Manual Pressure (MP)
Number of subjects: 42
Study 27177778 — intervention group
Group type: EXPERIMENTAL
Intervention: Food advertising literacy program (Experimental Group A)
Number of subjects: 140
Study 27177778 — intervention group
Group type: COMPARATOR
Intervention: Comparable knowledge-based nutrition education program (Experimental Group B)
Number of subjects: 140
Study 27177778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutrition education)
Number of subjects: 140
Study 23828464 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.15%
Number of subjects: 60
Study 23828464 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 60
Study 23828464 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.1%
Number of subjects: 60
Study 20707790 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 60 mg extended release (ER)
Number of subjects: 143
Study 20707790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 19362676 — intervention group
Group type: EXPERIMENTAL
Intervention: Avotermin 50 ng/100 microL per linear cm
Number of subjects: 0
Study 19362676 — intervention group
Group type: EXPERIMENTAL
Intervention: Avotermin (various concentrations)
Number of subjects: 0
Study 19362676 — intervention group
Group type: EXPERIMENTAL
Intervention: Avotermin 500 ng/100 microL per linear cm
Number of subjects: 0
Study 19362676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16549856 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening using PSA criteria
Number of subjects: 0
Study 16549856 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA threshold below 4.0 ng/mL
Number of subjects: 0
Study 14565966 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load strength training (80% of maximum, n = 11)
Number of subjects: 26
Study 14565966 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load steadiness training (n = 6)
Number of subjects: 26
Study 14565966 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load strength training and Heavy-load steadiness training
Number of subjects: 26
Study 14565966 — intervention group
Group type: COMPARATOR
Intervention: No training (n = 9)
Number of subjects: 26
Study 11352075 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vectorcardiography (cVCG) for 24 hours after admission, performed on 730 patients.
Number of subjects: 1016
Study 11352075 — intervention group
Group type: COMPARATOR
Intervention: Continuous 12-lead electrocardiography (c12ECG) for 24 hours after admission, performed on 286 patients.
Number of subjects: 1016
Study 11352075 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of cVCG and c12ECG results.
Number of subjects: 1016
Study 8691967 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol (100 mg increased to 200 mg twice daily, if tolerated)
Number of subjects: 3121
Study 8691967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3121
Study 8691967 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol
Number of subjects: 3121
Study 1755948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg)
Number of subjects: 12
Study 1755948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene (30 mg)
Number of subjects: 12
Study 1755948 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms)
Number of subjects: 12
Study 1755948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (3 mg)
Number of subjects: 12
Study 1755948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg)
Number of subjects: 12
Study 6296465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 gm every 12 hours)
Number of subjects: 21
Study 6296465 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (1 gm every 6 hours)
Number of subjects: 21
Study 31814316 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning walking group
Number of subjects: 60
Study 31814316 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon walking group
Number of subjects: 60
Study 31814316 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 30292734 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine)
Number of subjects: 196
Study 30292734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 27824277 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis DSM17250 extract (ointment formulation)
Number of subjects: 0
Study 24532827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitiered intervention with enhanced core reading instruction and additional 30-min daily small group intervention
Number of subjects: 267
Study 24532827 — intervention group
Group type: COMPARATOR
Intervention: Control condition with standard Tier 1 instruction (90 min whole group instruction)
Number of subjects: 267
Study 22963894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon
Number of subjects: 83
Study 22963894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21722952 — intervention group
Group type: EXPERIMENTAL
Intervention: txt2stop intervention (motivational messages and behavioural-change support)
Number of subjects: 5800
Study 19290689 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Naltrexone Therapy (BNT)
Number of subjects: 64
Study 19290689 — intervention group
Group type: COMPARATOR
Intervention: Compliance Enhancement (CE)
Number of subjects: 64
Study 17668969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% SnF2/sodium hexametaphosphate dentifrice
Number of subjects: 440
Study 17668969 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride/0.30% triclosan/copolymer dentifrice
Number of subjects: 440
Study 17668969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 440
Study 15151728 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 248
Study 15151728 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 248
Study 15151728 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF/ICSI (combined approach)
Number of subjects: 248
Study 12026536 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (Specific Immunotherapy) with mixed grass pollen allergens (Allergovit, Pollinex)
Number of subjects: 27
Study 12026536 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (Specific Immunotherapy) with mixed grass pollen allergens
Number of subjects: 27
Study 12026536 — intervention group
Group type: COMPARATOR
Intervention: Control group (before SIT)
Number of subjects: 27
Study 9824782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 0.05 mg/kg (3.5 mg for 70-kg body weight)
Number of subjects: 15
Study 9824782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7813412 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) monotherapy
Number of subjects: 50
Study 7813412 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT) monotherapy
Number of subjects: 50
Study 2221587 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 13
Study 2221587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2221587 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 13
Study 92624 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune plasma
Number of subjects: 0
Study 92624 — intervention group
Group type: COMPARATOR
Intervention: Normal plasma
Number of subjects: 0
Study 31155392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (0.5 mg/kg/6 hours)
Number of subjects: 35
Study 31155392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31155392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 35
Study 27460280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant)
Number of subjects: 573
Study 25844993 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 939
Study 25844993 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 939
Study 23683790 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fMRI scan including a cocaine‐cue reactivity task and a go no‐go response inhibition task
Number of subjects: 30
Study 21402578 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural sleep strategies delivered over one to three structured individual nurse consultations from 8 to 10 months
Number of subjects: 328
Study 21402578 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study 19473201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket PATH
Number of subjects: 30
Study 19473201 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study 17681066 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium sensitivity test (PST)
Number of subjects: 35
Study 17681066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder biopsy
Number of subjects: 35
Study 17681066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder cystoscopy
Number of subjects: 35
Study 14722400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cylindrical threaded titanium cage device
Number of subjects: 140
Study 14722400 — intervention group
Group type: COMPARATOR
Intervention: Femoral ring allograft control
Number of subjects: 140
Study 11313615 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Number of subjects: 15
Study 11313615 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham adjustment
Number of subjects: 15
Study 11313615 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 9222076 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg tablets (fasted)
Number of subjects: 12
Study 9222076 — intervention group
Group type: COMPARATOR
Intervention: Alatrofloxacin (IV infusion)
Number of subjects: 12
Study 9222076 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 100 mg tablets (after standard breakfast)
Number of subjects: 12
Study 9222076 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin 300 mg oral aqueous suspension (fasted)
Number of subjects: 12
Study 8107542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration with 1.5 l of water over 2 h after 24 h of dehydration
Number of subjects: 8
Study 8107542 — intervention group
Group type: COMPARATOR
Intervention: Euhydrated trial (ET)
Number of subjects: 8
Study 8107542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration trial (RT)
Number of subjects: 8
Study 8107542 — intervention group
Group type: COMPARATOR
Intervention: Dehydration
Number of subjects: 8
Study 8107542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration
Number of subjects: 8
Study 3105747 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein diet (median 92 g/day)
Number of subjects: 8
Study 3105747 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (47 g/day)
Number of subjects: 8
Study 29473700 — intervention group
Group type: EXPERIMENTAL
Intervention: C-isotope breath analysis (13 C breath tests)
Number of subjects: 15
Study 29473700 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 15
Study 27989522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy with hiatal hernia repair
Number of subjects: 100
Study 27989522 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy without hiatal hernia repair
Number of subjects: 100
Study 24472873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy targeting normal‐for‐age fasting blood glucose concentrations
Number of subjects: 100
Study 24472873 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion only to prevent excessive hyperglycemia
Number of subjects: 100
Study 22440371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1μg.kg(‐1) dexmedetomidine
Number of subjects: 60
Study 22440371 — intervention group
Group type: COMPARATOR
Intervention: 3μg.kg(‐1) fentanyl
Number of subjects: 60
Study 19397435 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 0
Study 19397435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural adaptations
Number of subjects: 0
Study 17488454 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 90
Study 17488454 — intervention group
Group type: COMPARATOR
Intervention: exfoliation syndrome
Number of subjects: 90
Study 15159198 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm support using the desk surface (Group 1)
Number of subjects: 59
Study 15159198 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 59
Study 15159198 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm support (after 6 weeks for Group 2)
Number of subjects: 59
Study 12234955 — intervention group
Group type: EXPERIMENTAL
Intervention: Paxil (20 mg/d) for 6 weeks
Number of subjects: 25
Study 12234955 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 25
Study 9637806 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus Clomiphene
Number of subjects: 61
Study 9637806 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Clomiphene
Number of subjects: 61
Study 9637806 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 61
Study 9637806 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 61
Study 7992821 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Panax ginseng
Number of subjects: 0
Study 7992821 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Panax quinquefolium roots
Number of subjects: 0
Study 7992821 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Ganoderma lucidum
Number of subjects: 0
Study 2532847 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin
Number of subjects: 168
Study 2532847 — intervention group
Group type: COMPARATOR
Intervention: Etretinate
Number of subjects: 168
Study 6388901 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care group
Number of subjects: 7825
Study 6388901 — intervention group
Group type: COMPARATOR
Intervention: Referred care group
Number of subjects: 7825
Study 31401237 — intervention group
Group type: COMPARATOR
Intervention: Food odors signaling sweet, savory, and sour taste (study 1)
Number of subjects: 96
Study 31401237 — intervention group
Group type: COMPARATOR
Intervention: Food odors signaling carbohydrates, protein, fat, and low-calorie food (study 2)
Number of subjects: 96
Study 28418492 — intervention group
Group type: EXPERIMENTAL
Intervention: PTM intervention (5 group workshops: 2 by audiologist, 3 by psychologist)
Number of subjects: 300
Study 28418492 — intervention group
Group type: EXPERIMENTAL
Intervention: PTM intervention
Number of subjects: 300
Study 28418492 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 300
Study 26189844 — intervention group
Group type: EXPERIMENTAL
Intervention: Venturi mask
Number of subjects: 65
Study 26189844 — intervention group
Group type: COMPARATOR
Intervention: Oxygen mask
Number of subjects: 65
Study 24268503 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 22404145 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg)
Number of subjects: 16
Study 22404145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21063110 — intervention group
Group type: EXPERIMENTAL
Intervention: Syzygium cumini aqueous leaves extract (ASc) at 100 μg/mL
Number of subjects: 0
Study 21063110 — intervention group
Group type: EXPERIMENTAL
Intervention: Syzygium cumini aqueous leaves extract (ASc) at 200 μg/mL
Number of subjects: 0
Study 21063110 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17409123 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed Rest plus Hypercortisolemia (BRHC)
Number of subjects: 0
Study 17409123 — intervention group
Group type: COMPARATOR
Intervention: Bed Rest (BR)
Number of subjects: 0
Study 17409123 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed Rest plus Essential Amino Acid and Carbohydrate Supplement (BRAA)
Number of subjects: 0
Study 15887586 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 50
Study 15887586 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar RFE
Number of subjects: 50
Study 15887586 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar RFE
Number of subjects: 50
Study 11820060 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (asa)
Number of subjects: 0
Study 9533996 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ear (RE) advantage for lexical decision task
Number of subjects: 26
Study 9533996 — intervention group
Group type: COMPARATOR
Intervention: Tone discrimination task
Number of subjects: 26
Study 7866479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic measurements of intra-abdominal depth
Number of subjects: 46
Study 7866479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic measurements of intra-abdominal muscle-vertebra distance
Number of subjects: 46